{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:27:18Z","timestamp":1767054438539,"version":"3.48.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04489-4","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:46:47Z","timestamp":1764060407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and correlates of hyperbilirubinemia among people living with HIV (PLHIV) receiving atazanavir boosted with ritonavir (ATV\/r)"],"prefix":"10.1186","volume":"25","author":[{"given":"Hameedreza","family":"Farrokhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elnaz","family":"Shahmohamadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ava","family":"Pashaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Emadi Koochak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Nooralioghli Parikhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Fathi Amrollah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pegah","family":"Mirzapour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ali","family":"Dehghan Manshadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SeyedAhmad","family":"SeyedAlinaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"4489_CR1","doi-asserted-by":"crossref","unstructured":"Kanmogne GDJC. HIV Infection, antiretroviral drugs, and the vascular endothelium. 2024;13(8):672.","DOI":"10.3390\/cells13080672"},{"key":"4489_CR2","doi-asserted-by":"crossref","unstructured":"Achenbach CJ, Darin KM, Murphy RL. Katlama cjfv: Atazanavir\/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. 2011;6(2):157\u201377.","DOI":"10.2217\/fvl.10.89"},{"key":"4489_CR3","doi-asserted-by":"crossref","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Medicine hosijnejo: declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. 1998;338(13):853\u201360.","DOI":"10.1056\/NEJM199803263381301"},{"key":"4489_CR4","unstructured":"Bethesda LJNID, Digestive, Diseases K. Clinical and research information on drug-induced liver injury. 2012."},{"key":"4489_CR5","unstructured":"Organization WH. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization; 2021."},{"key":"4489_CR6","doi-asserted-by":"crossref","unstructured":"Fukuda A, Nagao T, Kitaichi T, Koga I, Kobayashi A, Miura TJCMR. Opinion: safety analysis of lexiva tablets 700 (fosamprenavir calcium hydrate) in post-marketing surveillance in Japan. 2020;36(3):455\u201364.","DOI":"10.1080\/03007995.2019.1700495"},{"key":"4489_CR7","doi-asserted-by":"crossref","unstructured":"Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J. Sherman kejpotnaos: mechanism of indinavir-induced hyperbilirubinemia. 2001; 98(22):12671\u20136.","DOI":"10.1073\/pnas.231140698"},{"key":"4489_CR8","doi-asserted-by":"crossref","unstructured":"Molina J-M, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang RJTL. Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with Tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. 2008;372(9639):646\u201355.","DOI":"10.1016\/S0140-6736(08)61081-8"},{"key":"4489_CR9","doi-asserted-by":"crossref","unstructured":"Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss dP M, Knysz AA, Dietrich B, Phillips M, Lundgren A. JDJTL: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. 2003; 362(9377):22\u20139.","DOI":"10.1016\/S0140-6736(03)13802-0"},{"key":"4489_CR10","doi-asserted-by":"crossref","unstructured":"N\u00f3voa SR, Barreiro P, Rend\u00f3n A, Barrios A, Corral A, Jim\u00e9nez-Nacher I, Gonz\u00e1lez-Lahoz J. Soriano VJCid: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435\u00a0C\u2192 T polymorphism at the multidrug resistance gene 1. 2006; 42(2):291\u20135.","DOI":"10.1086\/499056"},{"key":"4489_CR11","unstructured":"WHO, Global HIV. Programme: treatment and care in adults. 2023 2\/16\/2023; Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-treatment-for-adults."},{"key":"4489_CR12","unstructured":"AIDSCT Group %J Rockville MUDoA. National Institute of Allergy, Disease I: Table of grading severity of adult adverse experiences. 1996."},{"key":"4489_CR13","unstructured":"Division of AIDS (DAIDS.) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 July 2017."},{"key":"4489_CR14","doi-asserted-by":"crossref","unstructured":"Moyle G, Else L, Jackson A, Back D, Yapa MH, Seymour N, Ringner-Nackter L, Karolia Z, Gazzard B, Boffito, MJAa et al. Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics. 2013;57(8):3640\u20134.","DOI":"10.1128\/AAC.00357-13"},{"key":"4489_CR15","doi-asserted-by":"crossref","unstructured":"Molina J-M, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang RJJJAIDS. Once-daily atazanavir\/ritonavir compared with twice-daily lopinavir\/ritonavir, each in combination with Tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1\u2013infected patients: 96-week efficacy and safety results of the CASTLE study. 2010;53(3):323\u201332.","DOI":"10.1097\/QAI.0b013e3181c990bf"},{"key":"4489_CR16","unstructured":"Landovitz RJ, Ribaudo HJ, Ofotokun I, Wang H, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, Team LJftAS. : Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTC\/tenofovir: ACTG 5257. In: Presented the Conference on Retroviruses and Opporutnistic Infections Boston, MA: 2014; 2014."},{"key":"4489_CR17","doi-asserted-by":"crossref","unstructured":"Ravi K, Devamsh G, Umesh K, Prashant BJAJIM. Study of Atazanavir-Induced hyperbilirubinemia among HIV patients on Second-Line Anti-Retroviral therapy. 2020;8(1):15\u20138.","DOI":"10.4103\/AJIM.AJIM_32_19"},{"key":"4489_CR18","doi-asserted-by":"crossref","unstructured":"Gesesew HA, Ward P, Woldemichael K. Mwanri ljpo: Prevalence, trend and risk factors for antiretroviral therapy discontinuation among HIV-infected adults in Ethiopia in 2003\u20132015. 2017; 12(6):e0179533.","DOI":"10.1371\/journal.pone.0179533"},{"key":"4489_CR19","doi-asserted-by":"crossref","unstructured":"Torti C, Lapadula G, Antinori A, Quirino T, Maserati R, Castelnuovo F, Maggiolo F, De Luca A, Paraninfo G, Antonucci FJI. Hyperbilirubinemia during Atazanavir treatment in 2,404 patients in the Italian Atazanavir expanded access program and MASTER cohorts. 2009;37(3):244\u20139.","DOI":"10.1007\/s15010-008-8010-6"},{"issue":"7","key":"4489_CR20","first-page":"378","volume":"27","author":"C Laprise","year":"2013","unstructured":"Laprise C, Baril J-G, Dufresne S, Trottier HJAPC. Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up. STDs. 2013;27(7):378\u201386.","journal-title":"STDs"},{"key":"4489_CR21","doi-asserted-by":"crossref","unstructured":"Bentu\u00e9-Ferrer D, Arvieux C, Tribut O, Ruffault A. Bellissant EJEoodm, toxicology: clinical pharmacology, efficacy and safety of atazanavir: a review. 2009; 5(11):1455\u201368.","DOI":"10.1517\/17425250903321514"},{"key":"4489_CR22","doi-asserted-by":"crossref","unstructured":"McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D, McGrath D, Farajallah A. Moyle GJApc, stds: clinical significance of hyperbilirubinemia among HIV-1\u2013Infected patients treated with Atazanavir\/Ritonavir through 96 weeks in the CASTLE study. 2012; 26(5):259\u201364.","DOI":"10.1089\/apc.2011.0092"},{"key":"4489_CR23","doi-asserted-by":"crossref","unstructured":"Merchante N, L\u00f3pez-Cort\u00e9s LF, Delgado-Fern\u00e1ndez M, R\u00edos-Villegas MJ, M\u00e1rquez-Solero M, Merino D, Pasquau J, Garc\u00eda-Figueras C, Mart\u00ednez-P\u00e9rez MA, Omar MJAPC et al. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400\/100\u00a0mg once daily in HIV\/hepatitis C virus-coinfected patients. 2011; 25(7):395\u2013402.","DOI":"10.1089\/apc.2011.0109"},{"key":"4489_CR24","doi-asserted-by":"crossref","unstructured":"Rodriguez JM, Hermida JM, Casado JL, Quereda C, Moreno A, Dronda F, Hernandez-Novoa B, Rodriguez MA, Perez-Elias MJ, Moreno SJA. The use of Atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score. 2011; 25(7):1006\u20139.","DOI":"10.1097\/QAD.0b013e3283466f85"},{"key":"4489_CR25","doi-asserted-by":"crossref","unstructured":"Alfano G, Cappelli G, Fontana F, Di Lullo L, Di Iorio B, Bellasi A. Guaraldi gjjocm: kidney disease in HIV infection. 2019;8(8):1254.","DOI":"10.3390\/jcm8081254"},{"key":"4489_CR26","doi-asserted-by":"crossref","unstructured":"Ejike OJ, Ikechukwu IK, Emmanuel OI, Owobi OE, Orji VU, Ozioko PC, et al. Effects of Dolutegravir and Protease Inhibitors based Regimen on Renal and Liver Function Markers of HIV Patients Attending Daughters of Charity Hospital Abuja. 2025;13(1):32\u201340.","DOI":"10.14741\/ijmcr\/v.13.1.4"},{"key":"4489_CR27","doi-asserted-by":"crossref","unstructured":"Uglietti A, Novati S, Gulminetti R, Maserati RJJMCR. Correlations between atazanavir Ctrough and hyperbilirubinemia: a case report. 2009;3(1):9307.","DOI":"10.1186\/1752-1947-3-9307"},{"key":"4489_CR28","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults. and Adolescents With HIV September 12,2024. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv."},{"key":"4489_CR29","unstructured":"Kane MJMGS. Atazanavir therapy and UGT1A1 genotype. 2023."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04489-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04489-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04489-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:22:52Z","timestamp":1767054172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04489-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4489"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04489-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"1. This study was conducted retrospectively by examining the clinical records of PLHIV treated with Atazanavir\/Ritonavir. Patients information was completely confidential and this information was extracted based on the code. In this study, we did not intervene with patient treatment. On the other hand, we did not have access to the patients so that we did not obtain written informed consent regarding being retrospective. The study protocol was reviewed and approved by the Institutional Review Board (IRB) of Tehran University of Medical Sciences (IR.TUMS.IKHC.REC.1398.005).2.\u00a0Ethics approval and consent to participate: Our study adhered to the Declaration of Helsinki in the context of research conducted on humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"883"}}